111. Congenital myopathy
7 clinical trials,   13 drugs   (DrugBank: 4 drugs),   1 drug target gene,   8 drug target pathways

Searched query = "Congenital myopathy", "Nemaline myopathy", "Central core disease", "Minicore myopathy", "Myotubular myopathy", "Centronuclear myopathy", "Congenital fiber-type disproportion myopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001147-51-SE
(EUCTR)
31/03/202027/09/2019This is a treatment study for a muscle disorder known as congenital myopathyCongenital myopathy intervention study - COMPIS Congenital myopathy
MedDRA version: 20.0;Level: PT;Classification code 10062547;Term: Congenital myopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Ventoline tablet 2mg
INN or Proposed INN: SALBUTAMOL SULFATE
Trade Name: Ventoline oral solution 0,4mg/ml
INN or Proposed INN: SALBUTAMOL SULFATE
Västra götalandsregionenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 4Sweden